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Abstract
Despite common use of antidepressants to treat postpartum depression, little is known
about the impact of antidepressant use on postpartum brain activity. Additionally, although
oxytocin has been investigated as a potential treatment for postpartum depression, the inter-
action between antidepressants and exogenous oxytocin on brain activity is unknown. We
explored postpartum depressed women’s neural activation in areas identified as important
to emotion and reward processing and potentially, antidepressant response: the amygdala,
nucleus accumbens and ventral tegmental area. We conducted a secondary analysis of a
functional imaging study of response to sexual, crying infant and smiling infant images in 23
postpartum depressed women with infants under six months (11 women taking antidepres-
sants, 12 unmedicated). Participants were randomized to receive a single dose of oxytocin
or placebo nasal spray. There was significantly higher amygdala activation to sexual stimuli
than either neutral or infant-related stimuli among women taking antidepressants or receiv-
ing oxytocin nasal spray. Among unmedicated women receiving placebo, amygdala activa-
tion was similar across stimuli types. There were no significant effects of antidepressants
nor oxytocin nasal spray on reward area processing (i.e., in the nucleus accumbens or ven-
tral tegmental area). Among postpartum women who remain depressed, there may be sig-
nificant interactions between the effects of antidepressant use and exogenous oxytocin on
neural activity associated with processing emotional information. Observed effect sizes
were moderate to large, strongly suggesting the need for further replication with a larger
sample.
Introduction
Antidepressants are a standard treatment for postpartum depression (PPD) [1]. However, the
effect of antidepressants on the postpartum brain are understudied, as most studies of
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antidepressant action have investigated males only [2]. This is a major knowledge gap, given
the sex/gender differences noted in antidepressant response [3] as well as in the systems that
underlie the putative antidepressant mechanisms such as serotonin transport [4] and func-
tional connectivity [5]. The experience of pregnancy, parturition, and providing maternal care
may alter neuroendocrine function in ways that interact with antidepressant actions [6, 7].
Also, there is increasing interest in the impact of antidepressants on neuroendocrine sys-
tems relevant to PPD. In particular, oxytocin–a neuropeptide that mediates social behaviors
such as maternal [8] and sexual behaviors [9]–may play a role in depression [10], particularly
in postpartum [11]. In postpartum women, oxytocin appears to facilitate adaptive reorganiza-
tion of key neural structures in the hypothalamus, hippocampus, and amygdala [12, 13].
Endogenous oxytocin during the postpartum period may also buffer against the negative
effects of cortisol and other aspects of stress reactivity [14–16]–a much needed adaptation to a
very stressful time of life. In fact, low endogenous oxytocin has been associated with risk of
PPD [11, 17, 18].
As oxytocin may play a role in PPD, exogenous oxytocin administration has been proposed
both as a primary treatment [19], or as an adjunctive to antidepressant treatment [20]. While
rodent models suggest exogenous oxytocin may improve PPD-like symptoms [21], clinical tri-
als in human mothers have not shown clear benefits [22–25]. These conflicting reports have
generally either excluded women taking antidepressants or considered medicated and unmed-
icated women together, complicating interpretation. Moreover, the effects of oxytocin on anti-
depressant action in depressed mothers are potentially different from a general depressed
population [26, 27], underscoring the need to examine interactions of oxytocin and antide-
pressant use in the context of PPD specifically.
As a secondary analysis of a previously collected dataset, we explored brain activity in
women with PPD who were or were not taking antidepressants, and who received either pla-
cebo or an oxytocin nasal spray. While the sample size is small, exploring these data could
reveal some clues for further study. Brain response data are scant for postpartum depressed
women, and there is even less known about PPD women on antidepressants. Because of the
vast amount of information collected during functional neuroimaging, it is particularly impor-
tant to have as much specificity as possible in pre-defining analyses; this specificity relies on
evidence from prior research. Thus, although the exploratory results in the present study are
in and of themselves only suggestive, they could be critical to future research. As such, we
explored neural activity in areas of most interest to researchers in the areas of emotion process-
ing and antidepressant treatment mechanisms.
Prior meta-analyses of mixed groups of depressed men and women (non-postpartum) have
indicated that antidepressant treatment is associated with changes in activation to visual emo-
tional stimuli in the limbic system, including the amygdala, and increased activation in the
mesolimbic “reward systems” including the nucleus accumbens (NAc) and ventral tegmental
area (VTA) [28]. Antidepressant response in non-postpartum depression has been predicted
by changes in activation to these areas [29–33]. The amygdala, VTA and NAc also appear to be
sites of significant structural and functional change during the postpartum period [34, 35].
Not surprisingly, these areas become particularly neuroplastic in response to the increased
oxytocin signaling during pregnancy and postpartum [36].
Although increased neuroplasticity is beneficial for adapting the brain to the new demands
of motherhood, it may also contribute to increased risk of PPD if reorganization is disrupted
(e.g., by significant life stressors [37, 38]), leading to persistently maladaptive patterns of acti-
vation [39]. This is particularly true for women with histories of early life stressors, as the
degree to which oxytocin release leads to increased neuroplasticity may depend on prior stress
experiences [40]. That is, women with a history of childhood trauma may be at increased risk
SSRIs & oxytocin in postpartum depression
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of reproductive mood disorders associated with the increased neuroplasticity induced by oxy-
tocin [41]. There is some evidence that antidepressants can reverse the structural modifica-
tions in the amygdala, VTA and NAc that may underlie PPD [37]. In rodent models of PPD,
postpartum depressive-like behavior is associated with structural changes to the NAc and
amygdala, but citalopram administration reverses these changes [42]. Similarly, while gesta-
tional stress appears to disrupt typical neuroplasticity in postpartum rats, these effects are
reversed with fluoxetine treatment [37, 43]. Based on these data, we selected the amygdala,
VTA, and NAc as our regions of interest (ROI): each has been shown relevant for antidepres-
sant response (including in PPD), each undergoes significant re-organization during the post-
partum period, and each has been shown to be responsive to oxytocin.
We hypothesized that, relative to unmedicated PPD women, PPD women taking antidepres-
sants would exhibit lower amygdala activation to sexual stimuli. In a non-postpartum context,
antidepressant use is associated with lower sexual interest in women [44], as well as lower amyg-
dala response to sexual images [45]. Healthy (non-depressed) postpartum women have signifi-
cantly lower amygdala response to sexual images than nulliparous women [46]; insofar as
antidepressants result in bringing PPD women’s neural responses closer to those of healthy post-
partum women, we should expect antidepressants to be associated with lower amygdala response
to sexual images. Furthermore, contrasting amygdala responses to sexual vs. infant related stimuli
may be a marker of initial neuroadaptation to motherhood, as increasing response to infant sti-
muli and decreasing response to sexual stimuli in the early months postpartum may reflect
increased investment in the current offspring vs. potential new offspring [46, 47]. Thus, we addi-
tionally hypothesized that, for activation of the amygdala and reward areas (VTA, NAc), the rela-
tive difference between infant and sexual images would be greater in PPD women taking
antidepressants than in unmedicated PPD women, in whom responses would be more muted.
As antidepressants have been shown to amplify reward activation in non-postpartum con-
texts [32, 48], we hypothesized that PPD women taking antidepressants would have signifi-
cantly higher VTA and NAc activation to positive emotional images (smiling infants, sexual
images) relative to unmedicated women. This means we expected different effects of antide-
pressants on amygdala vs. reward area processing of sexual images: decreasing activation in
the former while increasing the latter. Such effects would parallel report of women’s subjective
experience of postpartum sexuality: while women’s sexual interest decreases in the postpartum
period, the degree of pleasure from sexual activity remains stable [49, 50].
Animal models suggest that oxytocin may mediate some of the antidepressant effects of
SSRIs [51, 52], and data from clinical studies in humans show resting levels of oxytocin increase
following antidepressant administration [53].These findings hint at possible parallel mecha-
nisms underlying both antidepressant use and oxytocin response. Thus, we hypothesized that
the effects of oxytocin on neural activation to emotional stimuli would differ in women who
were taking vs. not taking antidepressants. If there are similar systems underlying the response
to both antidepressants and oxytocin in postpartum depressed women, we should expect the
effects of exogenous oxytocin to be relatively less noticeable among women taking antidepres-
sants. However, given the dearth of prior research, we did not have a priori hypotheses regard-
ing how the combination of exogenous oxytocin and antidepressants would impact contrasts
between stimuli types, or differences in activation of amygdala vs. reward processing areas.
Methods
The present study was a secondary analysis from a larger investigation of differences in neural
activity between postpartum and nulliparous women; detailed description of study procedures
can be found in the primary publications [46, 47, 54].
SSRIs & oxytocin in postpartum depression
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Participants
Women who were 3–6 months postpartum, breastfeeding at>75% of feedings, were recruited
and screened for depression with the Edinburgh Postnatal Depression Scale (EPDS, [55]).
Women with a history of psychosis or manic episodes were excluded. A total of 23 currently
depressed postpartum women (scoring� 12 on the EPDS) completed a scanning session and
provided complete data regarding medication use. Of these, 11 reported current use of an
SSRI antidepressant (sertraline, N = 8, fluoxetine, N = 2, citalopram, N = 1), while 12 reported
no antidepressant use. Both groups were similar in demographics (Table 1). Also, on the day
of the experimental session, participants completed the Center for Epidemiologic Study–
Depression scale (CES-D [56]); the medicated vs. unmedicated groups were similar in level of
self-reported depressive symptoms at the time of scanning.
Table 1. Demographics. There were no significant differences in demographics across medication group. CESD: Center for Epidemiologic Study–Depression scale.
Antidepressant group
(n = 11)
Unmedicated group
(n = 12)
Mean SD Mean SD
Age of participant (years) 30.82 4.94 30.17 5.47
CES-D Scale score on day of testing 23.73 9.00 24.91 12.13
Pre-trial urinary oxytocin (pg/mL) 10.01 6.64 9.76 6.74
n % n %
History of Psychotherapy
No history 2 18% 7 58%
Past, not current 2 18% 2 17%
Current 7 64% 3 25%
Menstrual period returned?
Yes 8 72% 7 58%
No 3 27% 5 42%
Race/Ethnicity
White 10 91% 8 66%
Non-white 1 9% 4 33%
Highest Education
High school 3 27% 4 33%
College degree 5 45% 7 58%
Postgraduate degree 3 27% 1 8%
Self-reported physical health
Fair 1 9% 2 17%
Good 9 81% 8 66%
Excellent 1 9% 2 17%
Lifetime number of live births
1 9 82% 8 66%
2 2 18% 2 17%
3 or more 0 0% 2 17%
Other medications on day of testing
None 8 10
Hormonal contraceptives 2 0
Antihistamines 1 1
Lansoprazole 0 1
Ibuprofen 1 0
https://doi.org/10.1371/journal.pone.0217764.t001
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Experimental procedure
To reduce variability in endogenous oxytocin, participants nursed their infant ~1 hour 15 min-
utes prior to imaging. All participants were administered nasal spray approximately 30 min
prior to imaging; nasal spray condition (oxytocin vs. placebo) was randomized and double-
blinded. Oxytocin nasal spray contained an inert carrier solution and 24IU of synthetic oxyto-
cin (Syntocinon, Novartis Pharma, Switzerland), while the placebo spray contained inert car-
rier only; these sprays have been shown to be indistinguishable to participants [57]. While the
elimination half-life of peripheral (plasma) oxytocin is relatively short (~20 minutes [58]), con-
centrations in cerebrospinal fluid peak approximately 45–75 minutes of nasal spray adminis-
tration [59].
Participants provided a urine sample before and after nasal spray application, which was
tested for oxytocin. These tests confirmed a significant increase in urinary oxytocin in the oxy-
tocin nasal spray group (Mpre = 7.29 pg/mL, SD = 2.14; Mpost = 44.37 pg/mL SD = 46.27; paired
t(10) = -2.63, p = .025), but not the placebo (Mpre = 12.34pg/mL, SD = 8.66; Mpost = 11.34 pg/
mL, SD = 11.80; paired t(10) = .25, p = .809). Baseline urinary oxytocin levels were similar
across medication groups (antidepressant M = 10.30 pg/mL, SD = 6.86; unmedicated M = 9.76
pg/mL, SD = 6.74), and were in the same range reported in prior research on urinary oxytocin
in postpartum women [60, 61]. Antidepressant use did not predict changes in urinary oxytocin
(F(1, 24) = 1.14, p = .296).
Following nursing and nasal spray administration, participants viewed emotionally relevant
visual stimuli in a functional magnetic resonance imaging (fMRI) paradigm (see below for
imaging details). We examined blood oxygenation-level dependent (BOLD) responses to 4 sti-
muli types: sexually explicit images, smiling and crying infant images, and emotionally neutral
images. The neutral images were derived from a set of International Affective Picture Set
(IAPS) images validated to evoke low emotional arousal and fall in the middle of the valence
range [47, 62]. Infant images were taken from publicly available websites and were validated to
evoke moderate but significant emotional arousal; given a Likert scale of 1 (least intense) to 9
(most intense), the average rating for infant images was 4.70 [46]. Sexual images included
images of nude heterosexual couples engaging in sexual acts (e.g., oral sex, vaginal intercourse)
that were derived from a set of images previously shown to evoke sexual interest in women
[46, 63]; these images similarly were rated as moderately but significantly emotionally arous-
ing, with an average intensity rating of 4.35 [46]. During stimuli presentation, participants
completed a backwards-matching task to ensure adequate attention. The study was approved
by the Institutional Review Board at Indiana University Bloomington, and all participants pro-
vided written informed consent.
Imaging procedures and data processing
The imaging session consisted of a 3 plane-localizing scan to determine slice volumes (10 sec),
seven whole brain blood oxygenation-level dependent (BOLD) scans (5 min each), and a
whole brain high-resolution anatomical scan (5 min), for a total of approximately 1 hour.
Functional (BOLD) scans were started with a 12-sec at-rest baseline, followed by 64 random-
ized stimuli presented for 2 seconds each (with variable inter-stimuli intervals of 2–6 seconds).
Imaging was conducted in a Seimens Magnetom Trio 3T whole body MRI. All images were
collected on a 32-channel phased-array head coil. The field of view of 220 × 220 mm. An in-
plane resolution of 128 × 128 pixels, and 35 axial slices of 3.4 mm thickness per volume, pro-
duced voxels that were 1.7 × 1.7 × 3.4 mm. A gradient echo BOLD echo-planar imaging (EPI)
sequence was used for capturing functional images, including the following parameters:
TE = 24 ms, TR = 2,000 ms, flip angle = 70˚. We used parallel imaging with an iPAT factor of
SSRIs & oxytocin in postpartum depression
PLOS ONE | https://doi.org/10.1371/journal.pone.0217764 May 31, 2019 5 / 16
2. For anatomical volumes, we used high-resolution T1-weighted images, acquired with a
Turbo-flash 3-D sequence, including the following parameters: TI = 900 ms, TE = 2.67 ms,
TR = 1800 ms, flip angle = 9˚, with 192 sagittal slices of 1 mm thickness, a field of view of
224 × 256 mm, and an isometric voxel size of 1 mm3.
We used BrainVoyager QX 2.2 to prepare imaging data for statistical analysis. Each partici-
pants’ anatomical volumes were stereotaxically transformed using the Talaraich atlas with an
eight-parameter affine transformation. Using an intensity-based motion correction algorithm,
functional volumes were realigned to the volume closest in time to the anatomic volume. We
also corrected functional volumes using slice scan-time correction, 3-D spatial Gaussian filter-
ing (FWHM 6 mm), and linear trend removal. These corrected functional volumes were co-
registered to the relevant anatomical volume using an intensity-based matching algorithm,
and normalized to the common stereotactic space with an eight-parameter affine transforma-
tion. Functional data were re-sampled to 3 mm3 isometric voxels. Beta weights of a random-
effects general linear model (based on timing protocol of the blocked stimulus presentation,
convolved with a two-gamma hemodynamic response function) were extracted from group
ROIs using the VOI/ROI ANCOVA data table tool in BrainVoyager’s volume of interest
module.
Results
We conducted repeated measures ANCOVAs with stimulus type (neutral, sexual, infant cry-
ing, or infant smiling) as the repeated measures variable, medication use and nasal spray
group (and their interaction) as fixed effects, and the following covariates: scores on the Center
for Epidemiological Studies-Depression (CES-D) scale on the day of the imaging session [56],
age, pre-trial urinary oxytocin level, and activation to nonsense images in which the pixels
from the other stimuli were scrambled. Controlling for activation to nonsense stimuli
accounted for individual differences in general activation to visual stimuli not related to emo-
tion or reward processing. None of the covariates differed significantly between groups, but
had considerable variance across the entire sample and were thus used to control for individual
differences at baseline. We conducted separate models predicting activation in the left amyg-
dala (Talairach coordinates: -19, -6, -10), right amygdala (Talairach coordinates: 15, -5, -9), left
NAc (Talairach coordinates: 11, 12, -8); right NAc (Talairach coordinates: -13, 10, 8), and
VTA (Talairach coordinates: 2, -23, -5).
Amygdala
The main effect of antidepressant use was non-significant (Left: F(1, 14) = 3.26, p = .09, η2partial =
0.19; Right: F(1, 14) = 1.052, p = .32, η2partial = 0.07) as was nasal spray condition (Left: F(1, 14) =
0.15, p = .71, η2partial = 0.01; Right: F(1, 14) = 1.052, p = .32, η2partial = 0.07). In other words, nei-
ther antidepressant use nor oxytocin administration were associated with overall higher or lower
amygdala activation. However, there was a significant interaction between medication, nasal
spray condition, and stimuli type (Left: F(2, 13) = 6.85, p = .01, η2partial = 0.51; Right: F(2, 12) =
3.67, p = .04, η2partial = 0.48; see Fig 1); thus, we conducted follow-up contrasts to examine the
nature of the interaction (see below).
Post-hoc specific contrast tests of amygdala activation by stimuli type. See Table 2 for
all specific contrasts; general patterns are summarized below.
The contrast of infant vs. sexual stimuli was of particular interest as a possible marker of
neuroadaptation to motherhood. The contrast between smiling infant vs. sexual stimuli was
significant in all groups except unmedicated women receiving placebo. That is, for women tak-
ing antidepressants and/or receiving oxytocin nasal spray, there was significantly greater
SSRIs & oxytocin in postpartum depression
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amygdala activation to sexual stimuli than smiling infant stimuli; however, for unmedicated
women receiving placebo there was no significant difference between stimuli types. The con-
trast between crying infant and sexual stimuli was significant only among unmedicated
women receiving oxytocin nasal spray; in this group amygdala activation to sexual stimuli was
significantly greater than to crying infant stimuli.
Contrasts between neutral and smiling infant stimuli were significant in unmedicated
women; however, the direction of this contrast differed by nasal spray group. In unmedicated
women receiving placebo, amygdala activity to smiling infant stimuli was significantly higher
than to neutral stimuli; however, among unmedicated women receiving oxytocin nasal spray,
amygdala activation to smiling infant stimuli was significantly lower than to neutral stimuli.
Finally, contrasts between neutral and crying infant stimuli, and between crying and smil-
ing infant stimuli, were non-significant across all groups.
Nucleus accumbens
The interaction between stimuli type, nasal spray condition and medication use on activation
of the NAc was non-significant (Left: F(2, 14) = 1.91, p = .18, η2partial = 0.32; Right: F(2, 14) =
0.36, p = .78, η2partial = 0.08). However, there was a significant interaction between nasal
spray condition and antidepressant use in activation of the right NAc (F(1, 14) = 5.66, p = .03,
η2partial = 0.29), such that unmedicated women receiving placebo nasal spray had significantly
higher right NAc activation to all stimuli than women receiving antidepressants and/or oxyto-
cin nasal spray (Fig 2).
Ventral tegmental area
There were no significant effects by stimuli type, nasal spray condition, or medication use, nor
any significant interaction in the VTA.
Discussion
We explored if antidepressant use and exogenous oxytocin administration were associated
with neural activation in postpartum depressed women. There were significant interactions
between stimuli type, (non-randomized) antidepressant use, and (randomized) exogenous
oxytocin administration in amygdala activation. However, antidepressant use and oxytocin
administration were not associated with activation in reward processing areas, such the ventral
tegmental area and the nucleus accumbens.
Fig 1. a-b. Activation of amygdala (1a: Left; 1b: Right) to visual emotional stimuli, controlling for age, CES-D
score, pre-trial urinary oxytocin, and activation to scrambled images. Contrast bars represent significant differences
between response to different stimuli types within the group (i.e., significant repeated measures effects). �: p< 0.05; ��:
p< 0.01.
https://doi.org/10.1371/journal.pone.0217764.g001
SSRIs & oxytocin in postpartum depression
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Table 2. Post-hoc simple contrasts between stimuli types by antidepressant use and nasal spray group. Significant within-group contrasts are highlighted in grey.
Contrasts Antidepressant x
placebo nasal spray
Antidepressant x
oxytocin nasal spray
Unmedicated x
placebo nasal spray
Unmedicated x
oxytocin nasal spray
Mdiff SE p d Mdiff SE p d Mdiff SE p d Mdiff SE p d
Right amygdala
Neutral vs.
crying infant
-0.22 0.37 0.56 0.22 -0.01 0.24 0.98 0.02 -0.03 0.34 0.92 0.03 0.16 0.38 0.68 0.16
Neutral vs.
smiling
-0.07 0.20 0.73 0.13 0.05 0.13 0.69 0.15 -0.67 0.18 <0.01 1.41 0.73 0.20 <0.01 1.38
Neutral vs.
sexual
-0.99 0.37 0.02 1.01 -0.53 0.24 0.05 0.83 -0.66 0.34 0.07 0.73 -0.98 0.38 0.02 0.97
Crying infant vs.
smiling infant
0.15 0.43 0.73 0.13 0.06 0.28 0.84 0.08 -0.64 0.40 0.13 0.60 0.57 0.44 0.21 0.49
Crying infant vs.
sexual
-0.77 0.45 0.11 0.65 -0.53 0.30 0.10 0.67 -0.63 0.42 0.16 0.57 -1.13 0.47 0.03 0.91
Smiling infant vs.
sexual
-0.92 0.40 0.04 0.87 -0.58 0.26 0.04 0.84 0.01 0.37 0.98 0.01 -1.71 0.41 <0.01 1.58
Mdiff SE p d Mdiff SE p d Mdiff SE p d Mdiff SE p d
Left amygdala
Neutral vs.
crying infant
-0.37 0.27 0.19 0.52 0.11 0.25 0.66 0.17 -0.08 0.29 0.79 0.10 0.54 0.32 0.12 0.64
Neutral vs.
smiling
-0.32 0.23 0.20 0.53 0.06 0.22 0.80 0.10 -0.72 0.26 0.01 1.05 0.97 0.28 <0.01 1.31
Neutral vs.
sexual
-1.16 0.26 <0.01 1.69 -0.41 0.24 0.11 0.65 -0.6 0.29 0.06 0.78 -0.74 0.32 0.03 0.87
Crying infant vs.
smiling infant
0.05 0.33 0.88 0.06 -0.06 0.31 0.86 0.07 -0.64 0.36 0.10 0.67 0.44 0.40 0.29 0.42
Crying infant vs.
sexual
-0.79 0.43 0.09 0.69 -0.53 0.39 0.20 0.51 -0.52 0.47 0.29 0.42 -1.28 0.51 0.03 0.95
Smiling infant vs.
sexual
-0.85 0.31 0.02 1.04 -0.47 0.29 0.13 0.61 0.12 0.34 0.74 0.13 -1.71 0.38 <0.01 1.70
https://doi.org/10.1371/journal.pone.0217764.t002
Fig 2. Activation of right nucleus accumbens to visual emotional stimuli, controlling for age, CES-D score, pre-
trial urinary oxytocin, and activation to scrambled images. There were no significant contrasts between different
stimuli types. �: p< 0.05.
https://doi.org/10.1371/journal.pone.0217764.g002
SSRIs & oxytocin in postpartum depression
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Only three studies have directly compared neural activity in depressed women who were vs.
were not taking antidepressants. Briceño et al. [64] found no significant differences in overall
neural response to facial emotional stimuli in depressed women who were and were not taking
antidepressants. However, as that study did not predesignate ROIs, it was not designed to
detect anything but very large whole-brain group differences. Yang et al. [65] examined
changes in neural activation to sexual stimuli before and after antidepressant treatment in 7
depressed non-postpartum women. Following antidepressant treatment, participants signifi-
cantly increased activation in the subcortical reward areas, notably the hypothalamus, septal
nuclei and parahippocampal gyrus, but not the amygdala. However, there may be important
differences in postpartum vs. non-postpartum women’s brain activity, particularly when con-
sidering reproductively relevant stimuli (such as the sexual stimuli used here). In non-postpar-
tum women, antidepressants suppress sexual response [44], but as seen in Fig 1, in our sample
of depressed postpartum women, women taking antidepressants did not have systematically
lower amygdala response to sexual stimuli compared to unmedicated women.
Wonch et al. [66] examined amygdala response to infant stimuli in depressed and non-
depressed postpartum mothers. Within their PPD group, there were no significant differences
in amygdala response among 13 medicated vs. 18 unmedicated women. However, these
authors did not include sexual stimuli, which may elicit stronger amygdala response [46].
Also, unlike in Wonch et al [66]’s paradigm, all the participants in our study nursed their
infants prior to imaging; it is possible that recent exposure to endogenous oxytocin may moder-
ate important differences between medication groups. Finally, the participants in our sample
also reported significantly higher EDPS scores (M = 13.32, SEM = 0.79) than those studied by
Wonch et al (M = 8.29, SEM = 0.84); possibly, the observed effects only emerge during more
severe depressive episodes.
Importantly, there were significant interactions between oxytocin administration and anti-
depressant use in amygdala responsivity to emotional stimuli. Unmedicated women and
women taking antidepressants responded differently to exogenous oxytocin administration,
suggesting the need for caution as oxytocin is evaluated as an adjunctive to antidepressant
treatment in PPD. There is evidence that depression is associated with lower responsivity to
positively valenced emotional stimuli [67]. In healthy non-depressed women, administration
of escitalopram is associated with lower amygdala activation to negative stimuli and higher
activation to positive stimuli [68]. These patterns are thought to indicate that antidepressants
attenuate hyper-reactivity to negative or stressful stimuli, while increasing reward salience
associated with positive stimuli [69]. Oxytocin, however, appears to inhibit serotonin signaling
in the dorsal raphe nucleus via suppression of activity in the amygdala [70]. As such, it is possi-
ble that instead of amplifying the effects of antidepressants on amygdala response to positive
emotional stimuli (as would be beneficial in an adjunctive treatment), oxytocin may attenuate
antidepressant response. As seen in Fig 1, we found that among PPD women taking antide-
pressants, oxytocin vs. placebo administration was associated with what appears to be lower
amygdala activation to sexual stimuli, and no difference in smiling infant stimuli–at a mini-
mum, we did not find evidence for increased amygdala responsiveness to positive emotional
stimuli. However, when considering the possible treatment efficacy of adjunctive oxytocin
there may be different effects of short-term and long-term exposure to exogenous oxytocin;
the data from the present study can only speak to the short-term effects of a single administra-
tion. It is possible that longer-term joint oxytocin/antidepressant administration would have
down-stream effects that could amplify therapeutic response, such as increasing production of
neurotrophic factors [21] or epigenetic changes in the expression of genes for key receptors
[71].
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Unexpectedly, there were few significant associations of antidepressant use or oxytocin
administration with reward area processing. We observed only one such association (namely,
that unmedicated women receiving placebo had higher right NAc activity overall than any
other group); as this association was not replicated bilaterally, it should be interpreted cau-
tiously. There is evidence that the left NAc has greater involvement in reward-related activa-
tion than the right [72], which may lead to different thresholds for detecting depression-
related attenuation of reward processing. For example, one study of unmedicated depressed
individuals (50% female) found reduced activation in the left but not right NAc [73]. It is pos-
sible that the higher sensitivity of the left NAc may have influenced our findings in the left but
not right NAc. It is also possible that due to our sample size, we missed some small but poten-
tially relevant effects in the right NAc and VTA. Alternatively, it is possible that antidepressant
and oxytocin doses, or the length of exposure, were insufficient to see significant associations
in reward areas. Notably, all of the women in this study were depressed at the time of imaging,
suggesting incomplete treatment response among the women taking antidepressants: we may
have seen greater results if participants were on a higher dose that better managed their
depressive symptoms.
The fact that we did see significant associations in the amygdala might suggest that the
amygdala was relatively more responsive to the effects of antidepressants and/or oxytocin than
the NAc or VTA. However, studies in animal models suggest the opposite: antidepressant
administration is associated with significant changes in the organization and activation of the
NAc but not the basolateral amygdala [42]. It is possible that the stimuli we used may have elic-
ited an emotional, but not necessarily rewarding, response. Of the few studies that have found
a significant effect of oxytocin administration on reward area processing in postpartum
women, most have used stimuli of the participant’s own infants [74–76]–a much more salient
and arguably more rewarding stimulus than stimuli of other people’s infants. It is also possible
that when participants nursed shortly prior to imaging, the natural rise in prolactin levels asso-
ciated with lactation may have temporary suppressed dopamine production which in turn
may have limited activation of these dopaminergic pathways [77] (but see also [78]). Finally, it
is possible these findings reflect a true null, in which neither oxytocin nor antidepressants are
associated with significant effects in reward processing areas among PPD women. If so, this
would require antidepressants to exert their therapeutic effect on depression via some other
process–for example, by improving corticolimbic connectivity [79] or decreasing the effect of
stress on functional reorganization during the postpartum period [42].
Our sample size was small; however, it is in keeping with similar studies [66], and we
observed a number of significant associations with medium to large effect sizes. These effect
sizes may serve as a reference point for future researchers in planning studies on neural activa-
tion in PPD women. They also signal the need for caution in interpreting null effects. In a few
instances (e.g., the main effect of antidepressants on amygdala activation across stimuli), the
observed associations were not statistically significant but the effect sizes were large enough to
suggest a larger sample would achieve significance. Overall, we view the effect sizes observed
in this analysis as large enough to suggest that further replication would be fruitful in revealing
important group-wise differences. In particular, it will be important to collect samples large
enough (and with enough precision) to examine the sub-regions of amygdala that contribute
to the observed differences associated with antidepressant use. Such analyses can reveal impor-
tant clues as to the mechanisms by which antidepressants exert their effects. For example, is a
growing literature that suggests that, regardless of treatment modality, antidepressant effects
are driven by neuroplastic changes specific to the basolateral amygdala [80–82]; however thus
far this literature has not extended to PPD.
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This was an observational study, and antidepressant use was not randomized; thus our con-
clusions must be tempered regarding the effects attributable solely to antidepressants. We can-
not conclude antidepressants are causally related to changes in neural activity. Lacking
randomization with a control group (or other means of controlling for the effect of treatment),
it is difficult to conclude what might be driving the differences described here. However, it
should be noted that randomizing PPD women to placebo (or no treatment) would raise ethi-
cal issues, and would only be warranted if there were sufficient evidence of the need for such a
trial–again, highlighting the importance of preliminary findings such as those presented here.
It is also possible that there were important differences between the participants who were and
were not taking antidepressants. Both groups reported similar CES-D scores, suggesting that
the women taking antidepressants may have had a more severe underlying depression that
only partially remitted in response to medication. To address these limitations, future research
would benefit from a design comparing a larger sample of PPD participants before and after
successful antidepressant treatment.
Further research is also needed to examine if antidepressant use during the postpartum
transition influences neuroadaptation: it has been proposed that increasing activation to
infant-related stimuli and decreasing activation to sexual stimuli may reflect the shift of emo-
tional processing resources from sexual interest to the demands of caring for an infant [47].
Our data suggested differences between women who were medicated vs. unmedicated in con-
trasts between reproductively relevant stimuli (i.e., sexual vs. infant-related stimuli), which
supported the view that PPD represents a maladaptation to the unique challenges of mother-
hood. These findings, alongside a growing literature in evolutionary medicine [46, 47, 54, 83],
underscore the need to consider the reproductive context in which PPD occurs when evaluat-
ing potential treatments.
Conclusions
We compared neural activation in women with PPD who were and were not taking antide-
pressants. Among PPD women receiving oxytocin nasal spray and/or those taking antidepres-
sants, there was significantly higher amygdala activation to sexual stimuli than to either
neutral or smiling infant stimuli. However, among unmedicated PPD women receiving a pla-
cebo nasal spray, amygdala activation to sexual stimuli was not significantly different from
activation to either neutral or infant-related stimuli. There was no consistent effect of antide-
pressant use or exogenous oxytocin administration in activation of reward areas (NAc, VTA).
These data will help inform and encourage further attention to the growing body of research
on the effects of psychoactive medication on neural function during the postpartum reproduc-
tive transition.
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